Want to see DE:DRW3 full AI Analyst Report?
Top Page
Draegerwerk AG & Co. KGaA
(XETRA:DRW3)
Select Model
Select Model
Rating:66Neutral
Price Target:
€104.00
▼(-6.47% Downside)
Action:Downgraded
Date:10/16/26
The score is primarily supported by improving financial performance and a conservatively positioned balance sheet, alongside an attractive-looking valuation (low P/E with a moderate dividend yield). This is offset by weak technical positioning, with the share price below the 20- and 50-day moving averages and only neutral momentum indicators.
Positive Factors
Revenue and profitability recovery
The post-2022 recovery combines strong TTM revenue growth with expanded gross, EBIT, and net margins. This indicates improving demand and operating execution, while creating a stronger earnings base that can support investment, customer retention, and business resilience over the next several quarters.
Negative Factors
Historical earnings volatility
The 2022 losses and continuing historical variability show that Dräger’s earnings are not yet consistently stable across operating conditions. This weakens confidence in the durability of current profitability and could make future investment capacity or shareholder returns less predictable during a downturn.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and profitability recovery
The post-2022 recovery combines strong TTM revenue growth with expanded gross, EBIT, and net margins. This indicates improving demand and operating execution, while creating a stronger earnings base that can support investment, customer retention, and business resilience over the next several quarters.
Read all positive factors
Draegerwerk AG & Co. KGaA (DRW3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.56B
Dividend Yield2.34%
Average Volume (3M)23.45K
Price to Earnings (P/E)10.6
Beta (1Y)0.72
Revenue Growth6.37%
EPS Growth71.55%
CountryDE
Employees16,009
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)9.14
Shares Outstanding8,600,000
10 Day Avg. Volume35,935
30 Day Avg. Volume23,453
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.80
Price to Sales (P/S)0.37
P/FCF Ratio7.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.7
Revenue Forecast (FY)€3.63B
Draegerwerk AG & Co. KGaA Business Overview & Revenue Model
Company Description
Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the h...
How the Company Makes Money
Dräger makes money primarily by selling medical and safety technology products, complemented by recurring revenue from consumables, accessories, and after-sales services tied to its installed base. In the Medical segment, revenue is generated from...
Draegerwerk AG & Co. KGaA Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.57B | 3.48B | 3.37B | 3.37B | 3.05B | 3.33B |
| Gross Profit | 1.64B | 1.52B | 1.51B | 1.46B | 1.24B | 1.54B |
| EBITDA | 412.10M | 384.83M | 351.68M | 318.33M | 62.63M | 421.65M |
| Net Income | 171.28M | 139.50M | 124.41M | 110.43M | -64.56M | 154.23M |
Balance Sheet | ||||||
| Total Assets | 3.18B | 3.28B | 3.09B | 3.09B | 3.11B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 198.46M | 284.06M | 248.18M | 279.36M | 319.50M | 577.38M |
| Total Debt | 388.38M | 405.11M | 395.58M | 471.38M | 361.95M | 348.01M |
| Total Liabilities | 1.52B | 1.65B | 1.56B | 1.69B | 1.79B | 1.92B |
| Stockholders Equity | 1.66B | 1.63B | 1.54B | 1.41B | 1.32B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 188.38M | 166.50M | 103.52M | 121.47M | -231.09M | 274.54M |
| Operating Cash Flow | 280.88M | 238.33M | 167.31M | 189.68M | -144.23M | 384.89M |
| Investing Cash Flow | -83.18M | -98.15M | -43.39M | -67.34M | 36.83M | -109.92M |
| Financing Cash Flow | -180.91M | -83.99M | -161.38M | -154.56M | -29.38M | -334.64M |
Draegerwerk AG & Co. KGaA Technical Analysis
Negative
111.20
Price Trends
112.07
Negative
102.27
Negative
94.97
Positive
Market Momentum
-4.75
Positive
34.88
Neutral
11.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW3, the sentiment is Negative. The current price of 111.2 is above the 20-day moving average (MA) of 111.00, below the 50-day MA of 112.07, and above the 200-day MA of 94.97, indicating a neutral trend. The MACD of -4.75 indicates Positive momentum. The RSI at 34.88 is Neutral, neither overbought nor oversold. The STOCH value of 11.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:DRW3.
Draegerwerk AG & Co. KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €3.02B | 20.49 | 5.52% | 1.61% | -0.06% | -38.81% | |
70 Outperform | €46.24B | 21.07 | 12.00% | 2.40% | -0.92% | 2.06% | |
67 Neutral | €804.70M | 16.65 | 19.49% | 1.65% | 4.42% | 35.68% | |
66 Neutral | €1.56B | 10.61 | 10.62% | 2.34% | 6.37% | 71.55% | |
60 Neutral | €273.51M | -575.00 | -0.17% | 2.61% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €1.53B | 43.42 | 4.19% | 1.71% | ― | ― |
* General Sector Average
DE:DRW3
Draegerwerk AG & Co. KGaA
98.40
22.96
30.43%
DE:AFX
Carl Zeiss Meditec
35.10
-11.08
-23.99%
DE:COP
CompuGroup Medical
28.75
5.00
21.04%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
13.30
-4.11
-23.61%
DE:SBS
STRATEC Biomedical
23.50
-2.31
-8.94%
DE:SHL
Siemens Healthineers AG
41.76
-6.44
-13.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.